Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy
© 2023. Springer Nature Limited..
While high-level evidence is lacking, numerous retrospective studies have depicted the value of supplemental oxygen in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, and its use should be encouraged where necessary. The clinical course and survival of patients with IPF who have been introduced to oxygen therapy is still not fully understood. The objective of this study was to clarify overall survival, factors associated with prognosis, and causes of death in IPF patients after the start of oxygen therapy. This is a prospective cohort multicenter study, enrolling patients with IPF who started oxygen therapy at 19 hospitals with expertise in interstitial lung disease. Baseline clinical data at the start of oxygen therapy and 3-year follow-up data including death and cause of death were assessed. Factors associated with prognosis were analyzed using univariable and multivariable analyses. One hundred forty-seven eligible patients, of whom 86 (59%) were prescribed ambulatory oxygen therapy and 61 (41%) were prescribed long-term oxygen therapy, were recruited. Of them, 111 died (76%) during a median follow-up of 479 days. The median survival from the start of oxygen therapy was 537 ± 74 days. In the univariable analysis, low body mass index (BMI), low forced vital capacity (FVC), low diffusion capacity (DLCO), resting hypoxemia, short 6 min-walk distance, and high COPD assessment test (CAT) score were significantly associated with poor prognosis. Multivariable analysis revealed low BMI, low FVC, low DLCO, low minimum SpO2 on 6MWT, and high CAT score were independent factors for poor prognosis. The overall survival of IPF patients after starting oxygen therapy is about 1.5 years. In addition to pulmonary function tests, 6MWT and patient reported outcomes can be used to predict prognosis more accurately.Clinical Trial Registration: UMIN000009322.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Scientific reports - 13(2023), 1 vom: 22. Aug., Seite 13664 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kataoka, Kensuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 24.08.2023 Date Revised 23.11.2023 published: Electronic UMIN-CTR: UMIN000009322 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-40508-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361064713 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361064713 | ||
| 003 | DE-627 | ||
| 005 | 20231226210808.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-40508-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM361064713 | ||
| 035 | |a (NLM)37608014 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kataoka, Kensuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2023 | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UMIN-CTR: UMIN000009322 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a While high-level evidence is lacking, numerous retrospective studies have depicted the value of supplemental oxygen in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, and its use should be encouraged where necessary. The clinical course and survival of patients with IPF who have been introduced to oxygen therapy is still not fully understood. The objective of this study was to clarify overall survival, factors associated with prognosis, and causes of death in IPF patients after the start of oxygen therapy. This is a prospective cohort multicenter study, enrolling patients with IPF who started oxygen therapy at 19 hospitals with expertise in interstitial lung disease. Baseline clinical data at the start of oxygen therapy and 3-year follow-up data including death and cause of death were assessed. Factors associated with prognosis were analyzed using univariable and multivariable analyses. One hundred forty-seven eligible patients, of whom 86 (59%) were prescribed ambulatory oxygen therapy and 61 (41%) were prescribed long-term oxygen therapy, were recruited. Of them, 111 died (76%) during a median follow-up of 479 days. The median survival from the start of oxygen therapy was 537 ± 74 days. In the univariable analysis, low body mass index (BMI), low forced vital capacity (FVC), low diffusion capacity (DLCO), resting hypoxemia, short 6 min-walk distance, and high COPD assessment test (CAT) score were significantly associated with poor prognosis. Multivariable analysis revealed low BMI, low FVC, low DLCO, low minimum SpO2 on 6MWT, and high CAT score were independent factors for poor prognosis. The overall survival of IPF patients after starting oxygen therapy is about 1.5 years. In addition to pulmonary function tests, 6MWT and patient reported outcomes can be used to predict prognosis more accurately.Clinical Trial Registration: UMIN000009322 | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Oda, Keishi |e verfasserin |4 aut | |
| 700 | 1 | |a Takizawa, Hajime |e verfasserin |4 aut | |
| 700 | 1 | |a Ogura, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Yoshikazu |e verfasserin |4 aut | |
| 700 | 1 | |a Akagawa, Shinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Seishu |e verfasserin |4 aut | |
| 700 | 1 | |a Kishaba, Tomoo |e verfasserin |4 aut | |
| 700 | 1 | |a Sakamoto, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Hamada, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwano, Kazuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ebina, Masahito |e verfasserin |4 aut | |
| 700 | 1 | |a Enomoto, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazaki, Yasunari |e verfasserin |4 aut | |
| 700 | 1 | |a Atsumi, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Shinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Tanino, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohnishi, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Suda, Takafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kondoh, Yasuhiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 13(2023), 1 vom: 22. Aug., Seite 13664 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:22 |g month:08 |g pages:13664 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-40508-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 22 |c 08 |h 13664 | ||